http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5496560-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_046ed2eefbaae50c7b0d4bdac87ae7d4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
| filingDate | 1994-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1996-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1db9dc6d955d4abeb8fb40c36ce27105 |
| publicationDate | 1996-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5496560-A |
| titleOfInvention | Borderline active dosage forms of beta blockers |
| abstract | For short-term therapy of transient functional cardiovascular symptoms, borderline active dosage forms of beta blockers are used which produce in the body only the borderline active concentrations of active ingredient which produce no significant changes in the physiological values in the cardiovascular system under resting conditions for the respective specific beta blocker used and significantly reduce adrenergically induced transient stimulation effects. Oral, transdermal, or topical dosage forms are particularly advantageous. A differentiated therapy of functional symptoms which does not exist with the customary dosage forms of beta blockers designed for long-term therapies is possible. Both the quality of life and the risk-benefit ratio of the beta blockers are improved. The duration of the therapy also does not have to be extended beyond the symptomatically required scale since no rebound danger exists after withdrawal. As an additional and now indication, this also permits the short-term use for the primary therapy of sleep disturbances, within the framework of vegetative syndromes, in particular, within the framework of postmenopausal symptoms. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011015261-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009018824-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018280323-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015306084-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005002554-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004254202-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005002554-A2 |
| priorityDate | 1993-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.